Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RESMED, INC.

(RMD)
  Report
Delayed Nyse  -  01:00 2022-11-25 pm EST
229.92 USD   +0.25%
11/23Insider Sell: Resmed
MT
11/22ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
GL
11/22ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Transcript : ResMed Inc. Presents at BofA Securities Global Healthcare Conference 2022, Sep-14-2022 08:05 AM

09/14/2022 | 04:05am EST
Mick, thank you so much for coming to our conference.Presenter SpeechMichael Farrell Happy to be here, Lyanne. Thank you for hosting us.QuestionLyanne Harrison So it's been a very interesting few...


ę S&P Capital IQ 2022
All news about RESMED, INC.
11/23Insider Sell: Resmed
MT
11/22ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Ma..
GL
11/22ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Ma..
AQ
11/17Resmed : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
11/17Resmed Inc : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
11/17ResMed Inc Provides Information to the Shareholders
CI
11/17Insider Sell: Resmed
MT
11/16ResMed Opens Manufacturing Centre in Singapore, Expanding Manufacturing Footprint to Su..
CI
11/16Resmed Inc. Appoints Sandeep Gulati as General Manager, South Asia
CI
11/16Resmed : Opens Manufacturing Centre in Singapore, Expanding Manufacturing Footprint to Sup..
PU
More news
Analyst Recommendations on RESMED, INC.
More recommendations
Financials (USD)
Sales 2023 3 987 M - -
Net income 2023 892 M - -
Net Debt 2023 808 M - -
P/E ratio 2023 37,2x
Yield 2023 0,79%
Capitalization 33 680 M 33 680 M -
EV / Sales 2023 8,65x
EV / Sales 2024 7,80x
Nbr of Employees 8 160
Free-Float 76,8%
Chart RESMED, INC.
Duration : Period :
ResMed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESMED, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 229,92 $
Average target price 251,67 $
Spread / Average Target 9,46%
EPS Revisions
Managers and Directors
Michael J. Farrell Director-Business Development
Robert Andrew Douglas Vice President-Corporate Marketing
Brett A. Sandercock Chief Financial Officer
Peter C. Farrell Non-Executive Chairman
Carlos M. Nunez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
RESMED, INC.-11.95%33 680
THERMO FISHER SCIENTIFIC-17.38%215 659
DANAHER CORPORATION-18.84%191 709
INTUITIVE SURGICAL, INC.-26.40%93 453
BOSTON SCIENTIFIC CORPORATION3.32%62 864
SIEMENS HEALTHINEERS AG-21.67%60 386